Souhaitez-vous accéder aux communiqués récents ?

Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination of cash and stock for serving as Chairman of Novartis. Dr. Reinhardt also to be compensated over the...

Group net sales of USD 14.0 billion grew 2% (+4% cc[1]) Core operating income of USD 3.7 billion (+3%, +6% cc) grew ahead of sales, improving core operating income margin Core EPS of USD 1.32...

Simbrinza offers a wide range of treatment possibilities due to its strong efficacy, providing sustained control and a 21%-35% reduction in intraocular pressure[1],[2],[3] Combines Brinzolamide...

Shareholders approve 16th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New compensation...

Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Dr. Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional...

Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on...

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year...

Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable[1] MenB disease is associated with a high human...

As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease[1] In the Phase III trial, most patients...

Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years    COMFORT-II follow-up results show Jakavi may...